IL13 and asthma: Some other investigational anti-IL-13 monoclonal antibodies, like lebrikizumab and tralokinumab, have also completed phase 3 trials in individuals with uncontrolled asthma, however, have not been approved because inconsistent efficacy in the different trials [75,76].